How Common Is Haemophilus Influenzae Type b (HIB) Disease?

Haemophilus influenzae type b disease has gone from one of the most common life-threatening childhood infections to a rarity in countries with routine vaccination, but the global picture is uneven. Before conjugate vaccines became available, Hib caused an estimated 8.13 million serious illnesses and roughly 371,000 deaths per year among children under five worldwide.¹ In countries that achieved high vaccination coverage, invasive Hib disease has dropped by well over 90 percent. Where the vaccine hasn’t reached, Hib remains a major killer of young children and the story of “how common” it is depends entirely on where you look.

The Pre-Vaccine Burden

To understand how common Hib disease is today, you need to know what it looked like before vaccination. In the United States during the late 1980s, active surveillance found an incidence of about 37 cases per 100,000 children under five each year.² Hib was the leading cause of bacterial meningitis in young children across much of the developed world, and it also caused severe pneumonia, epiglottitis (a swelling of the tissue near the windpipe that can block breathing), bloodstream infections, and bone and joint infections.

Globally, the numbers were staggering. Before widespread vaccination, the weighted worldwide incidence of Hib meningitis in children under five was about 57 per 100,000. When all forms of invasive Hib disease were counted except non-bacteremic pneumonia, the incidence rose to 71 per 100,000, translating to roughly 445,000 cases and at least 108,500 deaths per year. If you include non-bacteremic pneumonia, a conservative estimate puts the toll at more than 2.2 million infections and 520,000 deaths annually.³ These weren’t just statistics. In the pre-vaccine era, roughly one in 200 children in some high-income countries experienced invasive Hib disease before their fifth birthday.

How Vaccination Transformed the Numbers

The introduction of Hib conjugate vaccines in the late 1980s and 1990s changed the landscape faster than almost any other vaccination program in history. In the United States, the incidence of Hib disease among children under five dropped by 71 percent between 1989 and 1991 alone, and Hib meningitis fell by 82 percent between 1985 and 1991.² Those early declines continued. In population-level studies, the overall incidence of invasive Hib disease fell from about 6.4 per 100,000 per year to 0.3 per 100,000 after vaccination programs were established.⁴ That’s a drop of more than 95 percent.

A meta-analysis across eight trials found the Hib conjugate vaccine had a protective efficacy of about 84 percent against invasive Hib disease, 75 percent against meningitis, and 69 percent against pneumonia.⁵ Real-world effectiveness data from Italy, after 20 years of routine use, showed similar figures, with vaccine effectiveness estimated at 83 percent.⁶ These numbers may look modest compared to, say, the 95-plus percent efficacy figures associated with some other childhood vaccines, but the protection is amplified by a second layer: herd immunity.

The Herd Immunity Effect

Hib vaccines don’t just protect the person who gets the shot. They reduce carriage of the bacteria in the nose and throat, which is how Hib spreads between people. In an early study comparing vaccinated infants with unvaccinated controls, Hib carriage rates were about 1.5 percent in vaccinated children versus 6.3 percent in controls. Among children whose family members carried Hib, the difference was even more dramatic: about 9 percent of vaccinated children picked up the bacterium, compared with nearly 39 percent of unvaccinated children.⁷ Carriage rates were even lower among unvaccinated siblings of vaccinated children, a clear sign of herd protection spreading outward from the vaccinated child.

This herd effect is a big part of why Hib disease dropped so steeply. Modeling work has suggested that in a well-vaccinated population like the United States, a vaccine shortage that required deferring the booster dose could persist for about three years before herd immunity eroded enough for invasive Hib disease rates to climb noticeably in children under five.⁸ The United Kingdom learned this the hard way when it experienced a resurgence of Hib cases in the early 2000s after initially omitting a booster dose from its schedule, underscoring how important herd immunity is for sustained disease control.⁹

What Hib Disease Does to the Body

One reason public health experts pushed so hard for Hib vaccines is that the disease is not just common (or was) but devastating. About three-quarters of children who developed invasive Hib disease presented with either meningitis or epiglottitis.¹⁰ Meningitis is an infection of the membranes surrounding the brain and spinal cord, and Hib meningitis historically killed about 5 percent of the children it affected. Among survivors, lasting damage is common.

One well-known follow-up study of school-age children who survived Hib meningitis found that about 14 percent had persisting neurologic problems, including hearing loss (the most common), seizure disorders, and in one case hemiplegia with intellectual disability.¹¹ Other studies found the long-term picture could be even worse. Assessments of children who survived Hib meningitis revealed mental and psychomotor deficits in roughly 20 to 25 percent of cases at both short-term and long-term follow-up.¹² A study in the UK found that about 19 percent of children with Hib meningitis reported serious long-term problems, with an additional 12 percent of parents attributing other health issues to the infection.¹³ This burden of disability is part of why cost-effectiveness analyses consistently find the Hib vaccine cost-saving or highly cost-effective, even in low- and middle-income countries.¹⁴

Who Gets Hib Disease Today

In high-income countries with strong vaccination programs, Hib disease in children has become genuinely rare. But it hasn’t vanished. Data from England over the decade from 2012/13 to 2022/23 showed that the median age of people with invasive Hib disease was 51 years, and 84 percent of cases were in adults rather than children.¹⁵ The most common presentation was bacteremic pneumonia, accounting for over half of cases. The case-fatality rate was about 6 percent.

This shift toward adults reflects two things. Children are well protected by vaccination, so they largely don’t get Hib anymore. But adults, especially older adults, were never routinely vaccinated against Hib, and many have declining immune function. In the United States, the estimated average annual incidence of all invasive Haemophilus influenzae infections in people 65 and older was about 6.5 per 100,000, with a case-fatality rate of roughly 20 percent that climbed with age.¹⁶ A Spanish study found similar patterns: the incidence of invasive H. influenzae disease was about 6.8 per 100,000 in adults 65 and older versus 1.1 per 100,000 in younger adults, and 30-day mortality was about 21 percent.¹⁷ The most common conditions among those adult patients were immunosuppression, cancers, diabetes, and chronic lung disease.

People with specific immune deficits face higher risk. Patients with multiple myeloma, for example, had subprotective Hib antibody levels in 55 percent of cases, and those with chronic renal failure in 29 percent, compared to just 3 percent of healthy controls of similar age.¹⁸ Young patients with blood cancers or without a functioning spleen are also considered at elevated risk.¹⁹

Breakthrough Cases in Vaccinated Children

Although rare, Hib disease can occur in fully vaccinated children. Both failure to complete the full vaccine series and true vaccine failures (where a child gets all doses but still develops disease) have been documented. Italian surveillance showed that both scenarios contributed to the residual Hib cases in children during two decades of routine vaccination.⁶

Research into why true vaccine failures happen points to a subtle immune deficiency. Children who develop Hib disease despite being vaccinated appear to produce antibodies that are lower in quality — they bind less tightly to the Hib capsule, making them less effective at clearing the bacteria.²⁰ In some cases, the bacterium itself may play a role. A recent case report described invasive Hib disease in a fully vaccinated, otherwise healthy child, noting that genetic duplication in the bacterium’s capsule-producing region may have reduced how well the immune response targeted it.²¹

The type of combination vaccine used can also matter. The UK experienced a rise in Hib cases that coincided with the introduction of combination vaccines containing acellular pertussis (DTaP-Hib). A study found that children who received all three primary-series doses as DTaP-Hib had substantially higher odds of developing invasive Hib disease despite full vaccination, compared with children who received at least some doses of a different Hib vaccine formulation.²² Laboratory studies in animal models have confirmed that the immune response to the Hib component can be dampened when it is combined with certain acellular pertussis vaccines.²³ Multivalent conjugate vaccines using certain carrier proteins may be at particular risk for this kind of immune interference.²⁴ This is one reason many vaccination schedules now include a booster dose to shore up protection.

The Rise of Non-Typeable and Non-b Strains

Here’s where the epidemiology gets more nuanced. The Hib vaccine specifically targets the type b capsule. H. influenzae comes in six capsular serotypes (a through f) plus “non-typeable” strains that lack a capsule entirely. As type b has been driven down by vaccination, non-typeable strains have become the most common bloodstream isolate of H. influenzae in vaccinated populations.²⁵ In long-term surveillance data, the most frequent diagnosis shifted from Hib meningitis in the pre-vaccine era to pneumonia and bloodstream infections caused by non-type b strains afterward, while the overall incidence of non-b infections stayed roughly stable.⁴ That’s an important distinction: the vaccine didn’t cause a surge in other strains. It just removed the dominant one from the picture, making non-typeable strains more visible.

Non-typeable H. influenzae strains are responsible for a different set of problems than type b. They cause the vast majority of ear infections in children and are a major trigger of flare-ups in adults with chronic obstructive pulmonary disease.²⁶ Unlike Hib, they tend to cause localized infections rather than the deep invasive disease (meningitis, epiglottitis, bloodstream infections) that makes Hib so dangerous. There is no vaccine against non-typeable strains, and developing one is considered an important unmet need in infectious disease. Among older adults in the US, non-typeable strains accounted for the majority of invasive H. influenzae infections, at an incidence of about 5 per 100,000 in people 65 and older.¹⁶

Serotype a in Indigenous Communities

One emerging concern that doesn’t get enough attention is H. influenzae serotype a. Since the late 1990s, type a (Hia) has appeared as a significant cause of severe invasive disease in Indigenous populations in northern Canada, Alaska, and other parts of North America.²⁷ In some regions, Hia has essentially stepped into the epidemiological niche that Hib once occupied, causing meningitis and other severe infections in young children and carrying a case-fatality rate of around 10 percent.²⁸ Surveillance data from northwestern Ontario have confirmed this trend, with invasive Hia disease emerging in the post-Hib-vaccine era in Indigenous communities there.²⁹

The Hib vaccine offers no cross-protection against serotype a, because the capsules are chemically different. There is active discussion about whether a dedicated Hia conjugate vaccine should be developed, but it doesn’t yet exist. This means that for some of the world’s most geographically isolated and medically underserved communities, invasive H. influenzae disease remains a genuine and ongoing threat. It just isn’t type b anymore.

Global Disparities in Coverage and Burden

In 2000, before Hib vaccine had reached many low-income countries, an estimated 8.13 million serious Hib illnesses occurred worldwide, with roughly 371,000 deaths in children between 1 and 59 months of age.¹ Since then, the Hib vaccine has been introduced into most national immunization programs, often through the support of international organizations. But coverage remains uneven across countries, shaped by socioeconomic disadvantage, geographical barriers to healthcare access, and variation in health system capacity.³⁰

Where vaccination coverage is high and sustained, Hib disease has been nearly eradicated in children. Where coverage is patchy, delayed, or interrupted by supply issues or conflict, Hib continues to circulate, and children continue to die from a disease that is entirely preventable. The gap between those two realities remains one of the starkest inequities in global child health.

Surveillance Challenges and Misidentification

Accurate surveillance matters because it drives vaccination policy. If you can’t reliably tell whether a case is caused by type b or another serotype, you can’t accurately judge how well the vaccine is working. This turned out to be a real problem. A CDC analysis of invasive H. influenzae isolates from the late 1990s found that 40 percent of a sample of 141 isolates had discrepancies between traditional serotyping methods used by state health departments and molecular testing done at the CDC. Among 40 isolates initially called serotype b by traditional methods, 27 (68 percent) turned out not to carry the type b capsule genes at all when checked by PCR.³¹ In other words, a large fraction of reported Hib cases were actually something else, which could have overstated vaccine failure rates and understated the vaccine’s true impact.

Newer molecular methods have improved accuracy considerably. Direct real-time PCR assays can now detect and serotype H. influenzae directly from spinal fluid without needing to grow the bacteria in culture first, achieving 100 percent sensitivity and specificity when compared to culture-based methods.³² These faster, more reliable tools matter not only for individual diagnosis but also for getting an honest count of how many Hib cases are actually occurring, especially in settings where traditional lab infrastructure is limited.

How Carriage Rates Have Changed

One indirect but telling measure of how common Hib is comes from measuring how many children carry the bacterium in their nose and throat. In the pre-vaccine era, young children in group settings had Hib carriage rates that could exceed 5 percent. Vaccination has driven those numbers down. In a study of children in Tehran, Hib carriage was found in about 2.3 percent of vaccinated children compared with 3.4 percent of unvaccinated children.³³ Earlier studies in the UK found even more pronounced differences, with carriage in vaccinated infants about a quarter of that seen in unvaccinated controls.⁷ Lower carriage means fewer opportunities for transmission, which feeds back into herd immunity and continues to suppress disease even in children who may not have been fully vaccinated.

The practical upshot is that in well-vaccinated populations, the chance of encountering Hib at all has become extremely small. The bacterium hasn’t been eradicated — it still circulates at low levels — but the combination of individual vaccine protection and reduced community transmission has made invasive Hib disease in children a genuinely uncommon event in high-coverage settings. For adults, especially those with weakened immune systems, the picture is different, and the emergence of other serotypes means that “Haemophilus influenzae disease” as a broader category has not gone away even where type b has been controlled.